Why the study?
The growing relevance of genetics in cardiovascular diseases and cardiomyopathies extends to heart failure management, highlighting the need for collaboration between cardiologists and geneticists.
Genetic evaluation is increasingly important in the management of heart failure and cardiomyopathies for determining etiology, assessing risk, and guiding family screening.
Genetic testing may aid cardiomyopathy evaluation and family screening; leaves open prospective validation of therapeutic targets in heart failure.
Over the last decades, the relevance of genetics in cardiovascular diseases has expanded, especially in the context of cardiomyopathies. Its relevance extends to the management of patients diagnosed with heart failure (HF), given its capacity to provide invaluable insights into the etiology of cardiomyopathies and identify individuals at a heightened risk of poor outcomes. Notably, the identification of an etiological genetic variant necessitates a comprehensive evaluation of the family lineage of the affected patients. In the future, these genetic variants hold potential as therapeutic targets with the capability to modify gene expression. In this complex setting, collaboration among cardiologists, specifically those specializing in cardiomyopathies and HF, and geneticists becomes paramount to improving individual and family health outcomes, as well as therapeutic clinical results. This review is intended to offer geneticists and cardiologists an updated perspective on the value of genetic research in HF and its implications in clinical practice.
No takes yet. Share an insight, caveat, or question.
Palmieri et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: